In the latest trading session, 0.37 million EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) shares changed hands as the company’s beta touched 1.29. With the company’s most recent per share price at $6.96 changing hands around $0.31 or 4.59% at last look, the market valuation stands at $245.60M. EYPT’s current price is a discount, trading about -124.57% off its 52-week high of $15.63. The share price had its 52-week low at $2.19, which suggests the last value was 68.53% up since then. When we look at EyePoint Pharmaceuticals Inc’s average trading volume, we note the 10-day average is 0.52 million shares, with the 3-month average coming to 520.93K.
Analysts gave the EyePoint Pharmaceuticals Inc (EYPT) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.11. If we narrow down to specifics, the data shows that 0 out of 9 analysts rate the stock as a Sell, with a further 1 assigning it an Overweight rating. Of the remaining, 0 recommended EYPT as a Hold, 8 felt it is a Buy and 0 rated the stock as Underweight. EyePoint Pharmaceuticals Inc’s EPS for the current quarter is expected to be -$0.51.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) trade information
Instantly EYPT is in green as seen in intraday trades today. With action 8.68%, the performance over the past five days has been green. The jump to weekly highs of 6.98 on Friday, 11/17/23 added 4.59% to the stock’s daily price. The company’s shares are showing year-to-date upside of 98.73%, with the 5-day performance at 8.68% in the green. However, in the 30-day time frame, EyePoint Pharmaceuticals Inc (NASDAQ:EYPT) is -7.07% down. Looking at the short shares, we see there were 5.35 million shares sold at short interest cover period of 12.56 days.
The consensus price target for the stock as assigned by Wall Street analysts is $30.13, meaning bulls need an upside of 76.9% from its recent market value. According to analyst projections, EYPT’s forecast low is $20.00 with $55.00 as the target high. To hit the forecast high, the stock’s price needs a -690.23% plunge from its current level, while the stock would need to soar -187.36% for it to hit the projected low.
EyePoint Pharmaceuticals Inc (EYPT) estimates and forecasts
Data shows that the EyePoint Pharmaceuticals Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 0.95% over the past 6 months, a 6.98% in annual growth rate that is considerably lower than the industry average of 14.90%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2023 revenue estimates. The rating firms predict current quarter revenue for EyePoint Pharmaceuticals Inc will rise 56.00%, while the growth in revenue is estimated to hit 17.90% for the next quarter. Year-over-year growth is forecast to reach -6.60% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of $8.71 million. 4 analysts are of the opinion that EyePoint Pharmaceuticals Inc’s revenue for the quarter ending Mar 2024 will be $10.74 million. The company’s revenue for the corresponding quarters a year ago was $10.53 million and $7.68 million respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -17.30%. The estimates for the next quarter sales put growth at 39.80%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -18.96%. The 2023 estimates are for EyePoint Pharmaceuticals Inc earnings to increase by 26.48%.
EyePoint Pharmaceuticals Inc is expected to release its next quarterly earnings report on November 01.
EyePoint Pharmaceuticals Inc (NASDAQ:EYPT)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 10.43% of EyePoint Pharmaceuticals Inc shares while 95.03% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 106.09%. There are 95.03% institutions holding the EyePoint Pharmaceuticals Inc stock share, with Franklin Resources, Inc. the top institutional holder. As of Sep 29, 2023, the company held 11.76% of the shares, roughly 4.15 million EYPT shares worth $29.27 million.
Suvretta Capital Management, LLC holds the second largest percentage of outstanding shares, with 9.89% or 3.49 million shares worth $24.62 million as of Sep 29, 2023.
Among Mutual Funds, the top two as of Jul 30, 2023 were Franklin Strategic Series-Franklin Small Cap Growth Fund and Vanguard Total Stock Market Index Fund. With 1.68 million shares estimated at $11.84 million under it, the former controlled 4.76% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.52% of the shares, roughly 0.89 million shares worth around $6.28 million.